# Hypoparathyroidism FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/hypoparathyroidism

> 6 upcoming FDA catalysts in hypoparathyroidism: YORVIPATH (palopegteriparatide, ASND) on August 2027 (primary completion); YORVIPATH (palopegteriparatide, ASND) on Aug to Nov 2027 (topline data readout); canvuparatide (MBX) on January 2028 (primary completion); canvuparatide (MBX) on Jan to Apr 2028 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| May 23, 2025 | [Canvuparatide primary completion](https://sec-api.dev/pdufa/canvuparatide) | MBX | Hypoparathyroidism | completed | "NCT06465108 (Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-23 (ACTUAL); Lead Sponsor MBX Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465108)) |
| Q3 2025 | [Canvuparatide topline data readout](https://sec-api.dev/pdufa/canvuparatide) | MBX | hypoparathyroidism | scheduled | "Topline results for the Phase 2 Avail trial of canvuparatide in hypoparathyroidism on track for Q3 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000095017025104602/mbx-ex99_1.htm)) |
| Apr 2026 | [SEP-479 trial start](https://sec-api.dev/pdufa/sep-479) | SEPN | hypoparathyroidism | completed | "In April 2026, Septerna initiated a Phase 1 clinical trial of SEP-479, its potent, selective oral small molecule PTH1R agonist for the treatment of hypoparathyroidism." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1984086/000119312526216723/sepn-ex99_1.htm)) |
| Q3 2026 | [Canvuparatide trial start](https://sec-api.dev/pdufa/canvuparatide) | MBX | hypoparathyroidism | scheduled | "Phase 3 trial of once-weekly canvuparatide now recruiting: MBX remains on track to initiate a Phase 3 pivotal trial of once-weekly canvuparatide in chronic hypoparathyroidism in Q3 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000119312526336841/mbx-ex99_1.htm)) |
| August 27, 2026 | [Canvuparatide trial start](https://sec-api.dev/pdufa/canvuparatide) | MBX | Hypoparathyroidism | completed | "CARMEL, Ind., and BURLINGTON, Mass., August 27, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that the first patient has been dosed in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000119312526369674/mbx-ex99_1.htm)) |
| August 2027 | [YORVIPATH (palopegteriparatide) primary completion](https://sec-api.dev/pdufa/palopegteriparatide) | ASND | Hypoparathyroidism | scheduled | "NCT07706764 (A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07706764)) |
| Aug to Nov 2027 | [YORVIPATH (palopegteriparatide) topline data readout](https://sec-api.dev/pdufa/palopegteriparatide) | ASND | Hypoparathyroidism | scheduled | "NCT07706764 (A Study to Test the Effects and Safety of Palopegteriparatide in Adolescents With Long-term Hypoparathyroidism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ascendis Pharma A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07706764)) |
| January 2028 | [Canvuparatide primary completion](https://sec-api.dev/pdufa/canvuparatide) | MBX | Hypoparathyroidism | scheduled | "NCT07699471 (A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor MBX Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07699471)) |
| Jan to Apr 2028 | [Canvuparatide topline data readout](https://sec-api.dev/pdufa/canvuparatide) | MBX | Hypoparathyroidism | scheduled | "NCT07699471 (A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor MBX Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07699471)) |
| May 2028 | [MBX Biosciences, Inc. primary completion](https://sec-api.dev/companies/mbx/catalysts) | MBX | Hypoparathyroidism | scheduled | "NCT06531941 (Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor MBX Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06531941)) |
| May to Aug 2028 | [MBX Biosciences, Inc. topline data readout](https://sec-api.dev/companies/mbx/catalysts) | MBX | Hypoparathyroidism | scheduled | "NCT06531941 (Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-05 (ESTIMATED); Lead Sponsor MBX Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06531941)) |

## Drugs

- [Canvuparatide](https://sec-api.dev/pdufa/canvuparatide) (MBX)
- [SEP-479](https://sec-api.dev/pdufa/sep-479) (SEPN)
- [YORVIPATH (palopegteriparatide)](https://sec-api.dev/pdufa/palopegteriparatide) (ASND)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/hypoparathyroidism.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Hypoparathyroidism FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/hypoparathyroidism

```bibtex
@misc{secapidev_indications_hypoparathyroidism_20261116,
  title        = {Hypoparathyroidism FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/hypoparathyroidism}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_hypoparathyroidism_20261116","title":"Hypoparathyroidism FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/hypoparathyroidism","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
